Guidelines and policies for medical writers in the biotech industry: an update on the controversy.
Papers reporting the results of clinical trials written by medical writers employed by the biotech and pharmaceutical industries have been criticized for possible bias in presentation and failure to adhere to authorship guidelines. Several groups have attempted to address the concerns of journal editors, academics, regulators, and the general public by issuing guidelines and policies for the preparation of such material.
Foote
MaryAnn
M
Amgen Inc., Thousand Oaks, California, USA. mfoote@amgen.com
D001709:Biotechnology / Q000592:standards*; D002986:Clinical Trials as Topic / Q000592:standards*; D004282:Documentation / Q000592:standards*; D004345:Drug Industry / Q000592:standards*; D017408:Guidelines as Topic; D038622:Internationality; D016134:Organizational Policy; D010506:Periodicals as Topic / Q000592:standards*